Want to see AU:ATH full AI Analyst Report?
Total Valuation
Alterity Therapeutics has a market cap or net worth of AU$91.66M. The enterprise value is AU$32.34.
Market CapAU$91.66M
Enterprise ValueAU$32.34
Share Statistics
Alterity Therapeutics has 229,150,850 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding229,150,850
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Alterity Therapeutics’s return on equity (ROE) is -0.55 and return on invested capital (ROIC) is -57.61%.
Return on Equity (ROE)-0.55
Return on Assets (ROA)-0.51
Return on Invested Capital (ROIC)-57.61%
Return on Capital Employed (ROCE)-0.66
Revenue Per Employee0.00
Profits Per Employee-2.13M
Employee Count11
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Alterity Therapeutics is ―. Alterity Therapeutics’s PEG ratio is -0.33.
PE Ratio―
PS Ratio0.00
PB Ratio2.83
Price to Fair Value2.83
Price to FCF0.00
Price to Operating Cash Flow-3.86
PEG Ratio-0.33
Income Statement
In the last 12 months, Alterity Therapeutics had revenue of 0.00 and earned -23.40M in profits. Earnings per share was -0.11.
Revenue0.00
Gross Profit-115.54K
Operating Income-28.42M
Pretax Income-26.90M
Net Income-23.40M
EBITDA-28.30M
Earnings Per Share (EPS)-0.11
Cash Flow
In the last 12 months, operating cash flow was -22.52M and capital expenditures 22.52M, giving a free cash flow of 0.00 billion.
Operating Cash Flow-22.52M
Free Cash Flow0.00
Free Cash Flow per Share0.00
Dividends & Yields
Alterity Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.67
52-Week Price Change-19.60%
50-Day Moving Average0.50
200-Day Moving Average―
Relative Strength Index (RSI)32.71
Average Volume (3m)304.15K
Important Dates
Alterity Therapeutics upcoming earnings date is Mar 4, 2027, TBA (Confirmed).
Last Earnings DateFeb 25, 2026
Next Earnings DateMar 4, 2027
Ex-Dividend Date―
Financial Position
Alterity Therapeutics as a current ratio of 14.52, with Debt / Equity ratio of 0.45%
Current Ratio14.52
Quick Ratio14.52
Debt to Market Cap<0.01
Net Debt to EBITDA1.31
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Alterity Therapeutics has paid -3.50M in taxes.
Income Tax-3.50M
Effective Tax Rate0.13
Enterprise Valuation
Alterity Therapeutics EV to EBITDA ratio is -2.96, with an EV/FCF ratio of 0.00.
EV to Sales0.00
EV to EBITDA-2.96
EV to Free Cash Flow0.00
EV to Operating Cash Flow-3.73
Balance Sheet
Alterity Therapeutics has AU$37.32M in cash and marketable securities with AU$193.47K in debt, giving a net cash position of AU$37.12M billion.
Cash & Marketable SecuritiesAU$37.32M
Total DebtAU$193.47K
Net CashAU$37.12M
Net Cash Per ShareAU$0.16
Tangible Book Value Per ShareAU$0.20
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Alterity Therapeutics is AU$0.95, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price TargetAU$0.95
Price Target Upside86.27% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast-16.21%